Sacks Natalie 4

What Happened
Natalie Sacks, a director of Caribou Biosciences, was granted a derivative award for 45,000 shares on 2026-02-20. The Form 4 reports an acquisition price of $0.00 (transaction code A — award/grant). This was a compensation award (not a sale or an immediate exercise) and no cash was reported as paid.

Key Details

• Transaction date: 2026-02-20
• Transaction type/code: Award/Grant (A) — derivative security
• Shares awarded: 45,000; Price reported: $0.00 (no cash paid)
• Shares owned after transaction: Not reported in this filing
• Vesting: One‑twelfth of the award vests each month; fully vested on 2027-02-20, subject to continued service (Footnote F1)
• Filing status: Form filed on 2026-02-20 (timely in this filing)

Context
This is a time‑vesting derivative award (commonly RSUs or similar director compensation). The award does not represent an immediate market purchase or sale — underlying shares will vest over the next 12 months if service continues. Such awards are routine director compensation and do not, by themselves, indicate a buy or sell signal.